JP2024525206A5 - - Google Patents
Info
- Publication number
- JP2024525206A5 JP2024525206A5 JP2023579156A JP2023579156A JP2024525206A5 JP 2024525206 A5 JP2024525206 A5 JP 2024525206A5 JP 2023579156 A JP2023579156 A JP 2023579156A JP 2023579156 A JP2023579156 A JP 2023579156A JP 2024525206 A5 JP2024525206 A5 JP 2024525206A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weight
- granular
- phase
- total weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214099P | 2021-06-23 | 2021-06-23 | |
| US63/214,099 | 2021-06-23 | ||
| PCT/US2022/034433 WO2022271765A1 (en) | 2021-06-23 | 2022-06-22 | Pharmaceutical compositions of an epidermal growth factor receptor inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525206A JP2024525206A (ja) | 2024-07-10 |
| JP2024525206A5 true JP2024525206A5 (https=) | 2025-06-30 |
Family
ID=82608194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579156A Pending JP2024525206A (ja) | 2021-06-23 | 2022-06-22 | 上皮成長因子受容体阻害剤の医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240293323A1 (https=) |
| EP (1) | EP4358942A1 (https=) |
| JP (1) | JP2024525206A (https=) |
| CN (1) | CN117835970A (https=) |
| AR (1) | AR126195A1 (https=) |
| CA (1) | CA3223889A1 (https=) |
| IL (1) | IL309447A (https=) |
| TW (1) | TW202317120A (https=) |
| WO (1) | WO2022271765A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024523506A (ja) * | 2021-06-23 | 2024-06-28 | ブループリント メディシンズ コーポレイション | 上皮成長因子受容体阻害剤の塩及び結晶形態 |
| CN116554150B (zh) * | 2022-12-30 | 2025-12-19 | 苏州浦合医药科技有限公司 | 第四代egfr抑制剂 |
| WO2024249660A1 (en) * | 2023-05-31 | 2024-12-05 | Amgen Inc. | Compositions comprising sotorasib |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100297194A1 (en) * | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| WO2015152433A1 (en) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| MX392941B (es) * | 2016-09-07 | 2025-03-24 | Celgene Corp | Composiciones para comprimidos. |
| JP2024523506A (ja) * | 2021-06-23 | 2024-06-28 | ブループリント メディシンズ コーポレイション | 上皮成長因子受容体阻害剤の塩及び結晶形態 |
-
2022
- 2022-06-22 EP EP22744033.6A patent/EP4358942A1/en active Pending
- 2022-06-22 US US18/573,229 patent/US20240293323A1/en active Pending
- 2022-06-22 IL IL309447A patent/IL309447A/en unknown
- 2022-06-22 CN CN202280056648.3A patent/CN117835970A/zh active Pending
- 2022-06-22 JP JP2023579156A patent/JP2024525206A/ja active Pending
- 2022-06-22 WO PCT/US2022/034433 patent/WO2022271765A1/en not_active Ceased
- 2022-06-22 CA CA3223889A patent/CA3223889A1/en active Pending
- 2022-06-22 AR ARP220101626A patent/AR126195A1/es unknown
- 2022-06-22 TW TW111123289A patent/TW202317120A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5794650B2 (ja) | 難溶性薬物の溶解性改善製剤 | |
| JP2024525206A5 (https=) | ||
| JP6043281B2 (ja) | ４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］−１ｈ−キノリン−２−オンラクテート一水和物を含む医薬組成物 | |
| JP4999466B2 (ja) | 塩基性薬物又はその塩を含有するマトリックス型徐放性製剤およびその製造方法 | |
| JP6666254B2 (ja) | アンドロゲン受容体アンタゴニストの固体医薬組成物 | |
| JP5289338B2 (ja) | 医薬固形製剤及びその製造方法 | |
| US20090018175A1 (en) | Pharmaceutical excipient complex | |
| TW201328722A (zh) | 醫藥調配物 | |
| WO2013164257A1 (en) | New formulation | |
| US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
| TW201542212A (zh) | 包括恩曲他濱、泰諾福韋、地瑞那韋與利托那韋的單位劑量形式以及包括地瑞那韋與利托那韋的單體錠劑 | |
| WO2010120963A1 (en) | Tablet formulation for p38 inhibitor and method | |
| AU2016231883A1 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| KR20220077094A (ko) | 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물 | |
| EP3318279B1 (en) | Solid oral pharmaceutical compositions of lurasidone hydrochloride | |
| WO2020003196A1 (en) | Pharmaceutical composition of axitinib | |
| JP2021518422A (ja) | レナリドミドを含む医薬組成物 | |
| WO2022153330A1 (en) | Pharmaceutical compositions comprising acalabrutinib | |
| WO2023195954A1 (en) | A film coated tablet comprising a solid dispersion of selexi̇pag | |
| JP2019034914A (ja) | 良好な徐放性を有する、レボドパ含有小型化錠剤 | |
| JP7233852B2 (ja) | 変色が抑制された固形製剤 | |
| WO2020101596A2 (en) | A capsule composition comprising sunitinib | |
| WO2022162687A1 (en) | Pharmaceutical compositions comprising nilotinib | |
| WO2025212071A1 (en) | A solid dispersion of enzalutamide | |
| EP4398910A1 (en) | A capsule formulation comprising macitentan |